Investor Relations
Presentations & Press Releases
Stock Info
SEC Filings
Corporate Governance
Accelr8 Announces Renewal and Expansion of SCHOTT Microarray License, and Notice of Allowance for New Patent

Accelr8 Announces Renewal and Expansion of SCHOTT Microarray License, and Notice of Allowance for New PatentDENVER, Colo., September 22, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that Accelr8 and SCHOTT Technical Glass Solutions, GmbH (Jena, Germany) have renewed Accelr8's license to SCHOTT for Nexterion® microarraying slides using OptiChem® biocoatings. In addition to renewing the existing non-exclusive license, Accelr8 also granted to SCHOTT the right to sell OptiChem®-coated products for application in medical diagnostics. Previously, SCHOTT's license excluded medical diagnostic applications. The new right for diagnostic products allows SCHOTT to sell up to 20,000 units/year to any single customer. If the customer plans to exceed this volume, SCHOTT will refer the customer to Accelr8 to negotiate a direct license from Accelr8. In return for the license, SCHOTT paid $150,000 to Accelr8 for a license fee and nonrecourse pre-paid royalties. After reaching cumulative sales that generate the prepaid royalty amount, SCHOTT will pay additional cash royalties to Accelr8 for subsequent sales. The term for the renewed license continues through November 24, 2014. The new SCHOTT licensing rights join Accelr8's previous direct license to Nanosphere (NASDAQ: NSPH) in medical diagnostics. Accelr8's Web site includes OptiChem® information and links to SCHOTT Nexterion's® microarraying product Web site— Accelr8 also announced receipt of a Notice of Allowance from the US Patent Office for broadened protection of methods used in Accelr8's BACcel&#8482 culture-free, same-day pathogen diagnostic system. Previously issued patents include system protection in the US and international markets. According to David Howson, Accelr8's president, "we are pleased with Schott's decision to renew and expand its OptiChem® license in microarraying products. We believe that Schott's global marketing reach can help capture new opportunities in the microarraying market segment." "The new US patent expands our protection of fundamental methods unique to our BACcel&#8482 system. We believe that the new claims that join our growing patent estate confer protection over basic analytical principles, without limiting protection to a specific narrow method of applying them. In our opinion, this issuance significantly strengthens our intellectual property assets," Howson concluded. About Accelr8 Accelr8 Technology Corporation ( is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel&#8482 system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8's own products. Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events. Contact OR John Metzger, of Metzger Associates Tom Geimer, of Accelr8 Technology Corp. +1.303.786.7000, ext. 2202 +1.303.863.8088